Xencor Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xencor stock.
View analyst ratings for Xencor or view top-rated stocks.

8 Wall Street research analysts have issued 1-year price targets for Xencor's stock. Their XNCR stock forecasts range from $42.00 to $60.00. On average, they anticipate Xencor's stock price to reach $52.33 in the next year. This suggests a possible upside of 81.3% from the stock's current price.
View analysts' price targets for Xencor or view top-rated stocks among Wall Street analysts.

Xencor's stock was trading at $40.12 at the start of the year. Since then, XNCR shares have decreased by 28.1% and is now trading at $28.86.
View the best growth stocks for 2022 here.

Xencor is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Xencor.

Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $1.09. The biopharmaceutical company had revenue of $85.50 million for the quarter, compared to the consensus estimate of $26.17 million. Xencor had a trailing twelve-month return on equity of 15.74% and a net margin of 33.28%. The firm's revenue for the quarter was up 152.2% on a year-over-year basis. During the same period last year, the firm earned ($0.04) EPS.
View Xencor's earnings history.

6 employees have rated Xencor CEO Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among Xencor's employees.

Some companies that are related to Xencor include Sarepta Therapeutics (SRPT), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Intra-Cellular Therapies (ITCI), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Mirati Therapeutics (MRTX), Cerevel Therapeutics (CERE), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB) and Karuna Therapeutics (KRTX).
View all of XNCR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XNCR stock can currently be purchased for approximately $28.86.

Xencor (NASDAQ:XNCR) has a market capitalization of $1.72 billion and generates $275.11 million in revenue each year. The biopharmaceutical company earns $82.63 million in net income (profit) each year or $1.779990 on an earnings per share basis.

Xencor employs 254 workers across the globe.

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for Xencor is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at [email protected], or via fax at 626-305-0350.